The BALANCE Study

Yousef, Muhammad; Schannwell, C. M.; Köstering, Matthias; Zeus, Tobias; Brehm, Michael; Strauer, Bodo E.

doi:10.1016/j.jacc.2009.02.051

Cited by 213 publications

(54 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient with chest tightness, shortness of breath symptoms improved significantly and exercise tolerance had increased compared to previous levels. The outcomes were consistent with those reported earlier [4].…”

Section: Discussionsupporting

confidence: 91%

Left ventricular improvement due to allogeneic CB-MNCs transplantation in a chronic heart failure six-years after myocardial infarction

Zhu

Yue²,

Ruan

et al. 2017

Cardiol J.

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Left ventricular improvement due to allogeneic CB-MNCs transplantation in a chronic heart failure six-years after myocardial infarction

Zhu

Yue²,

Ruan

et al. 2017

Cardiol J.

View full text Add to dashboard Cite

“…Recently, cell based therapies have evolved in treating various ischemic 3–5 and dilated cardiomyopathies 6 , yet there is no clear cut consensus about which type of stems cells should be used and how should they be delivered to the affected myocardium 7 . The only definitive therapy for NICM remains heart transplantation, which is only available to a specific patient population.…”

Section: Introductionmentioning

confidence: 99%

Rationale and Design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (The POSEIDON-DCM Study)

Mushtaq

DiFede

Golpanian

et al. 2014

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

Background While accumulating clinical trials have focused on the impact of cell-therapy in patients with acute MI and ischemic cardiomyopathy, there are fewer efforts to examine cell-based therapy in patients with non-ischemic cardiomyopathy (NICM). We hypothesized that cell-therapy could have a similar impact in NICM. Methods/Results The POSIDEON-DCM trial is a phase I/II trial designed to address autologous vs. allogeneic bone marrow derived MSCs in patients with NICM. In this study, cells will be administered transendocardially with the NOGA injection-catheter system to patients (n=36) randomly allocated to two treatments groups: Group 1 (n=18 auto-hMSCs) and Group 2 (n=18 allo-hMSCs). The primary and secondary objectives are, respectively, to demonstrate the safety and efficacy of allo-hMSCS vs. auto-hMSCs in patients with NICM. Conclusions This study will establish safety of transendocardial injection of stem cells (TESI), compare phenotypic outcomes, and offer promising advances in the field of cell-based therapy in patients with NICM.

show abstract

“…There has been controversy over the possible efficacy and mechanism of BM treatment of MI focused around the persistence and function of stem cells in the myocardium [7,8,35], with findings both dismissing and supporting the trans-differentiation of non-cardiac lineage stem cells into functional cardiomyocytes and endothelial tissue. Despite these contradictions, there is a growing body of data from studies of bone marrow derived cell transplantation post-MI in animal models [9,[36][37][38] and human clinical trials [2,14,23,[39][40][41][42] that show improvements in heart function over the short and long term consistent enough to be retained in extensive meta-analysis [24]. The variability in reported data highlight the need to better understand what makes some cellular therapies successful whilst others effect no improvement.…”

Section: Discussionmentioning

confidence: 99%

Hematopoietic stem cells are a critical sub-population of whole bone marrow in the treatment of myocardial infarction

Davy¹,

Walker²,

Wong³

et al. 2013

SCD

View full text Add to dashboard Cite

Recent studies suggest that whole bone marrow (WBM) derived stem cells may facilitate recovery following myocardial infarction. However, the sub-population of WBM responsible for recovery remains uncertain. By adjusting the abundance of CD34 + LinNeg cells in human bone marrow we examined the relative significance of hematopoietic stem cells (HSC) in the recovery of cardiac function in a murine model of induced myocardial infarction. Enrichment of HSC by ~100-fold in WBM transplanted into mice significantly increased recovery of heart function and reduced scar size compared to transplantation of WBM depleted in HSC by ~10-fold (P < 0.05, and P < 0.01 respectively). Peri-infarct capillary density was significantly increased in recipients of HSC-enriched samples (P < 0.01) or WBM samples (P < 0.01) compared to controls. These results strongly suggest a critical role for HSC in the effective treatment of myocardial infarction with human bone marrow, and imply that enrichment of HSC may markedly benefit the clinical application of WBM treatments.

show abstract

The BALANCE Study

Abstract: BMC therapy leads to significant and longstanding improvements of LV performance as well as quality of life and mortality of patients after AMI. After BMC therapy, no side effects were observed, showing that BMC therapy is safe.

Cited by 213 publications

References 32 publications

Left ventricular improvement due to allogeneic CB-MNCs transplantation in a chronic heart failure six-years after myocardial infarction

Left ventricular improvement due to allogeneic CB-MNCs transplantation in a chronic heart failure six-years after myocardial infarction

Rationale and Design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (The POSEIDON-DCM Study)

Hematopoietic stem cells are a critical sub-population of whole bone marrow in the treatment of myocardial infarction

Contact Info

Product

Resources

About